Q-omics provides the consensus-scored RN7SL12P profile across patient tissues and cancer cell-line models. RN7SL12P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RN7SL12P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RN7SL12P RNA expression shows 12,917 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where RN7SL12P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL12P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL12P survival associations across molecular data types. RN7SL12P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL12P RNA expression–survival associations across cancer types. High RN7SL12P expression shows unfavorable associations in SKCM, KICH, UVM, ACC, PAAD and THCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RN7SL12P RNA expression.
This table summarizes RN7SL12P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL12P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL12P shows lower tumor expression in KIRC and KIRP and higher tumor expression in BLCA, COAD, LUSC and BRCA. The KIRC box plot shows higher RN7SL12P RNA expression in normal versus tumor tissue (log2 FC = −0.204, t-test p < 0.001).
This table shows molecular features associated with RN7SL12P in patient tissues and cancer cell lines. In patient samples, RN7SL12P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
